Minnesota Oncology

Sarcoma News

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Carbon Ion Beam Radiation Effective in Spinal Sarcomas (September 6, 2013)

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of cancers arising from fibrous tissue, adipose tissue... Continue Reading

Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)

In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)

In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading

Do Complementary Therapies Work? – Ask the expert about herbs, acupuncture, and other complementary therapies (November 4, 2011)

Live Web Chat with Barrie R. Cassileth, PhD, Chief, Integrative Medicine Service; Laurance S. Rockefeller Chair Integrative Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), click here for Dr. Cassileth’s bio Dr. Cassileth is a world-renowned... Continue Reading

CancerConnect Live Web Chat with Dr. Sidransky on Picking the Cancer Treatment That Works Best for You on Wednesday, November 2, 2011 at 6:00 PM Eastern Time (October 25, 2011)

Picking the Cancer Treatment That Works Best for You- Ask the Expert about Personalized Medicine Live Web Chat with David Sidransky, MD, Johns Hopkins Medicine, Baltimore, MD, click here for bio Dr. David Sidransky is an award-winning oncologist and... Continue Reading

Latest Sarcoma News By Stage


Ewing's Sarcoma Overview

Shorter Chemotherapy Intervals Effective in Ewing Sarcoma (November 1, 2012)

In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results of a study published in the Journal of Clinical... Continue Reading

Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading

Children with Ewing’s Sarcoma or Astrocytoma Most Likely to Experience Late Recurrence (February 19, 2010)

Late recurrence of childhood cancers appears to occur most often in Ewing’s sarcoma and astrocytoma, according to the results of a study published in the Journal of the National Cancer Institute. As cancer treatment has improved and evolved, the number... Continue Reading

More Ewing's Sarcoma Overview

General Sarcoma

Carbon Ion Beam Radiation Effective in Spinal Sarcomas (September 6, 2013)

Radiation therapy with carbon ions is a safe and effective treatment for people with inoperable spinal sarcomas, according to the results of a study published in Cancer. Sarcomas are a varied group of cancers arising from fibrous tissue, adipose tissue... Continue Reading

FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)

In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading

Halaven Promising in Soft-Tissue Sarcoma (September 26, 2011)

The chemotherapy drug Halaven™ (eribulin mesylate) may be a promising therapy for certain types of soft-tissue sarcoma. These findings were recently reported in the Lancet Oncology. Halaven—which was derived from a marine sponge—is a chemotherapy... Continue Reading

Stay on Top of Your Family History of Cancer (July 15, 2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Three Years of Treatment with Gleevec Improves Survival in Gastrointestinal Stromal Tumors (GIST) (June 9, 2011)

Treatment with Gleevec® (imatinib) for 3 years following surgery significantly improves survival compared with the standard one-year therapy for patients with gastrointestinal stromal tumors (GIST). GIST is a type of soft tissue sarcoma that develops... Continue Reading

More General Sarcoma

Soft Tissue Sarcomas

Sorry, there are no articles available for this cancer stage.

More Soft Tissue Sarcomas